[
  {
    "ts": null,
    "headline": "US Equity Indexes Mixed in Midday Trading",
    "summary": "US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec",
    "url": "https://finnhub.io/api/news?id=f8442f0c5284702712a8324ad450ea73758e73331c3e796075e3f2e34fd81747",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763140683,
      "headline": "US Equity Indexes Mixed in Midday Trading",
      "id": 137480142,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "US equity indexes were mixed in midday trading on Friday, with technology and energy leading the sec",
      "url": "https://finnhub.io/api/news?id=f8442f0c5284702712a8324ad450ea73758e73331c3e796075e3f2e34fd81747"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail",
    "summary": "Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.",
    "url": "https://finnhub.io/api/news?id=cfcb22f09701fbac5d2669247e78a7793c42809772cbda26932f72926554395f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763138713,
      "headline": "Bristol Myers Slouches 4% After Experts Say Its Heart Drug Will Fail",
      "id": 137480144,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.",
      "url": "https://finnhub.io/api/news?id=cfcb22f09701fbac5d2669247e78a7793c42809772cbda26932f72926554395f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Amgen: “Why Not Go Buy That?”",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why […]",
    "url": "https://finnhub.io/api/news?id=48e1ec3138a8d9763fb9d703c7758545fcd86b88a201f94ba71e1cbd7997e1e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763136788,
      "headline": "Jim Cramer on Amgen: “Why Not Go Buy That?”",
      "id": 137480145,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer highlighted the company’s breakthrough medicine, as he remarked: “We had Amgen on the show the other day, announcing a breakthrough in Repatha, its every other week injection squelches cholesterol to a level where it helps prevent heart attacks. Why […]",
      "url": "https://finnhub.io/api/news?id=48e1ec3138a8d9763fb9d703c7758545fcd86b88a201f94ba71e1cbd7997e1e0"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Judge to Decide on Texas AG's Bid to Block Kenvue's Dividend",
    "summary": "A Texas judge will weigh Texas Attorney General Ken Paxton's bid to block Kenvue's (KVUE) November d",
    "url": "https://finnhub.io/api/news?id=9bebdd8eb044b085b9c9068064f0a40bb51a7b410d1c11d51d15e04ff7642e57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763131352,
      "headline": "Market Chatter: Judge to Decide on Texas AG's Bid to Block Kenvue's Dividend",
      "id": 137480146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "A Texas judge will weigh Texas Attorney General Ken Paxton's bid to block Kenvue's (KVUE) November d",
      "url": "https://finnhub.io/api/news?id=9bebdd8eb044b085b9c9068064f0a40bb51a7b410d1c11d51d15e04ff7642e57"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Premarket Friday",
    "summary": "Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL",
    "url": "https://finnhub.io/api/news?id=1b11f933c9b7d8453aa001032d1eaa57de642da24b7099d2c5a1ee77ce3944d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763129990,
      "headline": "Sector Update: Health Care Stocks Decline Premarket Friday",
      "id": 137480147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL",
      "url": "https://finnhub.io/api/news?id=1b11f933c9b7d8453aa001032d1eaa57de642da24b7099d2c5a1ee77ce3944d4"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
    "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
    "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763125140,
      "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
      "id": 137480131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
      "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee"
    }
  },
  {
    "ts": null,
    "headline": "Update on Phase 3 Librexia ACS Trial",
    "summary": "PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial",
    "url": "https://finnhub.io/api/news?id=2a32b682e6137496434c6c5202a5f3b9b78e654a1120afa4de3ffcf364c082d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763121540,
      "headline": "Update on Phase 3 Librexia ACS Trial",
      "id": 137480149,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 14, 2025--Update on Phase 3 Librexia ACS Trial",
      "url": "https://finnhub.io/api/news?id=2a32b682e6137496434c6c5202a5f3b9b78e654a1120afa4de3ffcf364c082d0"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why",
    "summary": "Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click for my look at the MRK and CDTX deal.",
    "url": "https://finnhub.io/api/news?id=394d9262b103694619c954892caa6a9eb2c5131d8ac7fda0896095ed07092cdb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763117788,
      "headline": "Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why",
      "id": 137479337,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2222078293/image_2222078293.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click for my look at the MRK and CDTX deal.",
      "url": "https://finnhub.io/api/news?id=394d9262b103694619c954892caa6a9eb2c5131d8ac7fda0896095ed07092cdb"
    }
  }
]